ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Jan 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
February 2026
Nuclear Technology
December 2025
Fusion Science and Technology
November 2025
Latest News
Radium sources yield cancer-fighting Ac-225 in IAEA program
The International Atomic Energy Agency has reported that, to date, 14 countries have made 14 transfers of disused radium to be recycled for use in advanced cancer treatments under the agency’s Global Radium-226 Management Initiative. Through this initiative, which was launched in 2021, legacy radium-226 from decades-old medical and industrial sources is used to produce actinium-225 radiopharmaceuticals, which have shown effectiveness in the treatment of patients with breast and prostate cancer and certain other cancers.
Joetta Goda, Caiser Bravo, Theresa Cutler, Travis Grove, David Hayes, Jesson Hutchinson, George McKenzie, Alexander McSpaden, William Myers, Rene Sanchez, Jessie Walker
Nuclear Science and Engineering | Volume 195 | Number 1 | November 2021 | Pages S55-S79
Technical Paper | doi.org/10.1080/00295639.2021.1947103
Articles are hosted by Taylor and Francis Online.
The work presented in this paper focuses on the first 10 years (2011–2020) of Godiva IV operations at the National Criticality Experiments Research Center (NCERC). Godiva IV is a fast burst critical assembly constructed of approximately 65 kg of highly enriched uranium fuel alloyed with 1.5% molybdenum for strength. Godiva is one of the last such critical assemblies in the United States and can be used for studies of super-prompt-critical behavior as well as irradiations and demonstrations. An overview of the startup of Godiva IV at NCERC is given followed by a summary of the experiments performed utilizing Godiva IV over the first 10 years of operation at NCERC.